Description overdue on 15.02.2012

Antiallergic agent . The mechanism of action is based on the stabilization of the membranes mast cells . The main active ingredient is the current cromoglicic acid . Intal impedes the process of mast cell degranulation, blocks the flow of calcium in them, inhibits the release of leukotrienes, bradykinin, histamine   and other bioactive compounds from mast cells. The drug prevents formation bronchospasm.   The most frequently used as a prevention of the allergic response. With prolonged use of marked decrease in the frequency of seizures suffocation   bronchial asthma, the disease is facilitated, reducing the need to use glucocorticosteroids   and bronchodilators. Stable effect is recorded through a 1 ½-month application. When a single application of the effect lasts up to five hours. Available in a metered aerosol, spray, drops, capsules and solution for inhalation.

Indications and contraindications:

Intal Aerosol is used for the prevention and therapy of anti-allergic hay fever, allergic rhinitis (seasonal, year-round flow types). Other forms of the drug are shown in COPD, bronchoconstriction, bronchial asthma (prevention of attacks). Intal is not indicated in pediatric patients until the age of five during pregnancy and breastfeeding. In the pathology of renal drug is administered in small doses with caution.

Side effect:

Digestive system:   dryness in the mouth, the use of aerosol causes bad taste in the mouth. Respiratory system:   cough, hoarseness, irritation of the respiratory tract. Nervous system:   recurrent headaches, dizziness, weakness. The urinary system : Violation of the renal system, urinary retention. Perhaps the development of allergic reactions such as swelling of the eyelids, face, lips, tearing, anaphylaxis , Skin rashes. Use of the drug Intal may be accompanied by difficulty, stridor, unstable blood pressure.

Mode of application:

Intal as drops instilled every 5 hours into each nasal passage 4 drops .  After achieving the desired therapeutic effect of the interval between the use of drugs is gradually increased .  Nasal sprays, nasal spray used 5 times a day for 1 injection .  Duration of treatment - a month .  Canceling the drug is carried out gradually over the week .  Intal capsules with powder for inhalation: for the prevention of asthma attacks swallow capsules inefficient .  With spinhalera carried inhalation powder .  20 mg (1 capsule) applied four times a day: a day at intervals of 3-6 hours night and morning .  If necessary, the dosage may be increased to 160 mg per day .  Intal dose aerosols for inhalation: 1 dose contains 1 mg of active substance applied four times a day for 2-10 mg .  Dosage can be increased to 2 mg with up to 8 times per day .  After achieving the desired therapeutic effect of switching to maintenance dosage, which allows optimal control of the disease .  In severe pathology amount of the drug is increased to 20 mg, four times a day .  Cancel medicament is carried out during the week, gradually .  Solution for Inhalation: using the inhaler used four times a day to 20 mg .  Before applying the contents of the bottle should be thoroughly shaken .  During inhalation, the metering valve must be located at the bottom, and the bottle in the upright position .

Special instructions:

Cromoglicic acid can provoke an attack of bronchospasm, dysuria Cough, swelling of the parotid glands. The dose reduction during a drug the patient must be monitored by the attending physician, reduction rate is calculated as follows: 10% for 1 week. A gradual decrease in the dosage of the drug can prevent worsening of the disease. With long-term animal studies and teratogenicity carcinogenic effects   the drug was observed.

Drug Interactions:

Glucocorticoids, beta-blockers, theophylline, antihistamines, and increase the efficiency of INTA. Application kromoglitsievoy acid can reduce the dosage of simultaneously prescribed corticosteroids. In the form of inhalation solution is incompatible with Intal ambroxol   and bromhexine. Bronchodilators are used immediately before inhalation.